Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA GlobeNewswire December 31, 2025 ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the […]